Use of farnesoid X receptor agonists to treat nonalcoholic fatty liver disease

Digestive Diseases

Volumn 33, Issue 3, 2015, Pages 426-432

  Sanyal, Arun J ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Bile acids; Cirrhosis; Farnesoid X receptor; Fibrosis; HDL cholesterol; Insulin resistance; LDL cholesterol; NAFLD activity score; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; BILIRUBIN; FARNESOID X RECEPTOR; HORMONE RECEPTOR STIMULATING AGENT; INSULIN; OBETICHOLIC ACID; PLACEBO; TRIACYLGLYCEROL; 6-ETHYLCHENODEOXYCHOLIC ACID; CELL RECEPTOR; CHENODEOXYCHOLIC ACID; FARNESOID X-ACTIVATED RECEPTOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; BILIRUBIN BLOOD LEVEL; CONFERENCE PAPER; CONSTIPATION; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG MEGADOSE; DRUG POTENCY; DRUG WITHDRAWAL; HEADACHE; HUMAN; INNATE IMMUNITY; INSULIN RESISTANCE; LIPID METABOLISM; LIVER FIBROSIS; LIVER INJURY; MOLECULAR PATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; ATHEROSCLEROSIS; DRUG EFFECTS; LIVER CIRRHOSIS; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE;

ANIMALS; ATHEROSCLEROSIS; CHENODEOXYCHOLIC ACID; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; LIVER CIRRHOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 84930580432     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000371698     Document Type: Conference Paper

References (66)

1. Loomba R, Sanyal AJ: The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013; 10: 686-690.
2. Brunt EM: Nonalcoholic steatohepatitis: pathologic features and differential diagnosis. Semin Diagn Pathol 2005; 22: 330-338.
3. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S: Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-873.
4. Adams LA, Harmsen S, St Sauver JL, Charatcharoenwitthaya P, Enders FB, Therneau T, Angulo P: Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: A community-based cohort study. Am J Gastroenterol 2010; 105: 1567-1573.
5. Hai S, Kubo S, Shuto T, Tanaka H, Takemura S, Yamamoto T, Kanazawa A, et al: Hepatocellular carcinoma arising from nonalcoholic steatohepatitis: report of two cases. Surg Today 2006; 36: 390-394.
6. Sanyal A, Poklepovic A, Moyneur E, Barghout V: Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin 2010; 26: 2183-2191.
7. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, et al: Nonalcoholic fatty liver disease: A feature of the metabolic syndrome. Diabetes 2001; 50: 1844-1850.
8. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, et al: NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-379.
9. Vos MB: Nutrition, nonalcoholic fatty liver disease and the microbiome: recent progress in the field. Curr Opin Lipidol 2014; 25: 61-66.
10. Bugianesi E, McCullough AJ, Marchesini G: Insulin resistance: A metabolic pathway to chronic liver disease. Hepatology 2005; 42: 987-1000.
11. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR: CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000; 105: 1067-1075.
12. Zhao H, Przybylska M, Wu IH, Zhang J, Maniatis P, Pacheco J, Piepenhagen P, et al: Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice. Hepatology 2009; 50: 85-93.
13. Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, Sargeant C, et al: A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007; 46: 1081-1090.
14. Choi S, Diehl AM: Role of inflammation in nonalcoholic steatohepatitis. Curr Opin Gastroenterol 2005; 21: 702-707.
15. Xu ZJ, Fan JG, Wang XP, Wang GL: Upregulating expressions of hepatic lipopolysaccharide receptors in nonalcoholic steatohepatitic rats (in Chinese). Zhonghua Gan Zang Bing Za Zhi 2006; 14: 49-52.
16. Musso G, Gambino R, Cassader M: Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders. Curr Opin Lipidol 2010; 21: 76-83.
17. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, Thaiss CA, et al: Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012; 482: 179-185.
18. Malhi H, Gores GJ: Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 2008; 28: 360-369.
19. Malhi H, Gores GJ: Cellular and molecular mechanisms of liver injury. Gastroenterology 2008; 134: 1641-1654.
20. Cusi K: Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 2012; 142: 711-725. e6.
21. Bjursell M, Wedin M, Admyre T, Hermansson M, Bottcher G, Goransson M, Linden D, et al: Ageing Fxr deficient mice develop increased energy expenditure, improved glucose control and liver damage resembling NASH. PLoS One 2013; 8:e64721.
22. Cariou B, van Harmelen K, Duran-Sandoval D, van Dijk TH, Grefhorst A, Abdelkarim M, Caron S, et al: The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem 2006; 281: 11039-11049.
23. Savage DB, Petersen KF, Shulman GI: Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev 2007; 87: 507-520.
24. Miyata M, Sakaida Y, Matsuzawa H, Yoshinari K, Yamazoe Y: Fibroblast growth factor treatment ameliorates disruption of hepatic lipid metabolism in farnesoid X receptor (Fxr)-null mice. Biol Pharm Bull 2011; 34: 1885-1889.
25. Miyata M, Hata T, Yamakawa H, Kagawa T, Yoshinari K, Yamazoe Y: Involvement of multiple elements in FXR-mediated transcriptional activation of FGF19. J Steroid Biochem Mol Biol 2012; 132: 41-47.
26. Schreuder TC, Marsman HA, Lenicek M, van Werven JR, Nederveen AJ, Jansen PL, Schaap FG: The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. Am J Physiol Gastrointest Liver Physiol 2010; 298:G440-G445.
27. Tomlinson E, Fu L, John L, Hultgren B, Huang X, Renz M, Stephan JP, et al: Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002; 143: 1741-1747.
28. Dufer M, Horth K, Wagner R, Schittenhelm B, Prowald S, Wagner TF, Oberwinkler J, et al: Bile acids acutely stimulate insulin secretion of mouse beta-cells via farnesoid X receptor activation and K(ATP) channel inhibition. Diabetes 2012; 61: 1479-1489.
29. De Fabiani E, Mitro N, Gilardi F, Caruso D, Galli G, Crestani M: Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-tofed cycle. J Biol Chem 2003; 278: 39124-39132.
30. Ma K, Saha PK, Chan L, Moore DD: Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 2006; 116: 1102-1109.
31. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, Willson TM, et al: Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA 2006; 103: 1006-1011.
32. Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA, Moore DD, et al: Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004; 113: 1408-1418.
33. Kast HR, Nguyen CM, Sinal CJ, Jones SA, Laffitte BA, Reue K, Gonzalez FJ, et al: Farnesoid X-activated receptor induces apolipoprotein C-II transcription: A molecular mechanism linking plasma triglyceride levels to bile acids. Mol Endocrinol 2001; 15: 1720-1728.
34. Claudel T, Inoue Y, Barbier O, Duran-Sandoval D, Kosykh V, Fruchart J, Fruchart JC, et al: Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology 2003; 125: 544-555.
35. Zhang S, Wang J, Liu Q, Harnish DC: Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol 2009; 51: 380-388.
36. Li F, Jiang C, Krausz KW, Li Y, Albert I, Hao H, Fabre KM, et al: Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun 2013; 4: 2384.
37. Vavassori P, Mencarelli A, Renga B, Distrutti E, Fiorucci S: The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol 2009; 183: 6251-6261.
38. Hageman J, Herrema H, Groen AK, Kuipers F: A role of the bile salt receptor FXR in atherosclerosis. Arterioscler Thromb Vasc Biol 2010; 30: 1519-1528.
39. Gadaleta RM, Oldenburg B, Willemsen EC, Spit M, Murzilli S, Salvatore L, Klomp LW, et al: Activation of bile salt nuclear receptor FXR is repressed by pro-inflammatory cytokines activating NF-kappaB signaling in the intestine. Biochim Biophys Acta 2011; 1812: 851-858.
40. Fausther M, Dranoff JA: New insights on the pathogenesis of biliary cirrhosis provided by studies in FXR knockout mice. J Hepatol 2011; 55: 939-940.
41. Li J, Zhang Y, Kuruba R, Gao X, Gandhi CR, Xie W, Li S: Roles of microRNA-29a in the antifibrotic effect of farnesoid X receptor in hepatic stellate cells. Mol Pharmacol 2011; 80: 191-200.
42. Fiorucci S, Antonelli E, Rizzo G, Renga B, Mencarelli A, Riccardi L, Orlandi S, et al: The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 2004; 127: 1497-1512.
43. Fiorucci S, Cipriani S, Mencarelli A, Baldelli F, Bifulco G, Zampella A: Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA. Mini Rev Med Chem 2011; 11: 753-762.
44. Ghebremariam YT, Yamada K, Lee JC, Johnson CL, Atzler D, Anderssohn M, Agrawal R, et al: FXR agonist INT-747 upregulates DDAH expression and enhances insulin sensitivity in high-salt fed Dahl rats. PLoS One 2013; 8:e60653.
45. Maneschi E, Vignozzi L, Morelli A, Mello T, Filippi S, Cellai I, Comeglio P, et al: FXR activation normalizes insulin sensitivity in visceral preadipocytes of a rabbit model of MetS. J Endocrinol 2013; 218: 215-231.
46. Mencarelli A, Cipriani S, Renga B, D'Amore C, Palladino G, Distrutti E, Baldelli F, et al: FXR activation improves myocardial fatty acid metabolism in a rodent model of obesitydriven cardiotoxicity. Nutr Metab Cardiovasc Dis 2013; 23: 94-101.
47. Prawitt J, Abdelkarim M, Stroeve JH, Popescu I, Duez H, Velagapudi VR, Dumont J, et al: Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes 2011; 60: 1861-1871.
48. Cariou B, van Harmelen K, Duran-Sandoval D, van Dijk T, Grefhorst A, Bouchaert E, Fruchart JC, et al: Transient impairment of the adaptive response to fasting in FXR-deficient mice. FEBS Lett 2005; 579: 4076-4080.
49. Cipriani S, Mencarelli A, Palladino G, Fiorucci S: FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res 2010; 51: 771-784.
50. Bilz S, Samuel V, Morino K, Savage D, Choi CS, Shulman GI: Activation of the farnesoid X receptor improves lipid metabolism in combined hyperlipidemic hamsters. Am J Physiol Endocrinol Metab 2006; 290:E716-E722.
51. Chao F, Gong W, Zheng Y, Li Y, Huang G, Gao M, Li J, et al: Upregulation of scavenger receptor class B type I expression by activation of FXR in hepatocyte. Atherosclerosis 2010; 213: 443-448.
52. Hambruch E, Miyazaki-Anzai S, Hahn U, Matysik S, Boettcher A, Perovic-Ottstadt S, Schluter T, et al: Synthetic farnesoid X receptor agonists induce high-density lipoproteinmediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice. J Pharmacol Exp Ther 2012; 343: 556-567.
53. Chennamsetty I, Claudel T, Kostner KM, Baghdasaryan A, Kratky D, Levak-Frank S, Frank S, et al: Farnesoid X receptor represses hepatic human APOA gene expression. J Clin Invest 2011; 121: 3724-3734.
54. Guo GL, Santamarina-Fojo S, Akiyama TE, Amar MJ, Paigen BJ, Brewer B Jr, Gonzalez FJ: Effects of FXR in foam-cell formation and atherosclerosis development. Biochim Biophys Acta 2006; 1761: 1401-1409.
55. Bishop-Bailey D, Walsh DT, Warner TD: Expression and activation of the farnesoid X receptor in the vasculature. Proc Natl Acad Sci USA 2004; 101: 3668-3673.
56. Hollman DA, Milona A, van Erpecum KJ, van Mil SW: Anti-inflammatory and metabolic actions of FXR: insights into molecular mechanisms. Biochim Biophys Acta 2012; 1821: 1443-1452.
57. Edwards PA, Kast HR, Anisfeld AM: BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. J Lipid Res 2002; 43: 2-12.
58. Porez G, Prawitt J, Gross B, Staels B: Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J Lipid Res 2012; 53: 1723-1737.
59. Cassader M, Gambino R, Musso G, Depetris N, Mecca F, Cavallo-Perin P, Pacini G, et al: Postprandial triglyceride-rich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients. Lipids 2001; 36: 1117-1124.
60. Siddiqui MS, Sterling RK, Luketic VA, Puri P, Stravitz RT, Bouneva I, Boyett S, et al: Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis. Gastroenterology 2013; 145: 1271-1279. e1-3.
61. Kong B, Luyendyk JP, Tawfik O, Guo GL: Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. J Pharmacol Exp Ther 2009; 328: 116-122.
62. Miyazaki-Anzai S, Levi M, Kratzer A, Ting TC, Lewis LB, Miyazaki M: Farnesoid X receptor activation prevents the development of vascular calcification in ApoE-/-mice with chronic kidney disease. Circ Res 2010; 106: 1807-1817.
63. Hanniman EA, Lambert G, McCarthy TC, Sinal CJ: Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice. J Lipid Res 2005; 46: 2595-2604.
64. Hartman HB, Gardell SJ, Petucci CJ, Wang S, Krueger JA, Evans MJ: Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/-and apoE-/-mice. J Lipid Res 2009; 50: 1090-1100.
65. Zhang Y, Wang X, Vales C, Lee FY, Lee H, Lusis AJ, Edwards PA: FXR deficiency causes reduced atherosclerosis in Ldlr-/-mice. Arterioscler Thromb Vasc Biol 2006; 26: 2316-2321.
66. Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, Adorini L, et al: Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013; 145: 574-582. e571.